Mala Healthcare Private Limited, 1401 Terra, Planet Godrej, KK Marg, Mumbai 400011

Focused on Healthcare, Pharma, and Biotech in Asia including India

Competitive Advantage

Management Team

Strategy and Execution

Executive Summary

India – Growing Market ($45 Billion by 2020* McKinsey Report)

Health Awareness

Large population

Government Reforms

Cost-effective

Manufacturing

Higher Health Expenditures

Growing Per capita Income

Unmet Needs

India Advantage

“Future innovations will flow from the rise of capital-scarce but labor-abundant nations like India and China”

Diana FarrellMcKinsey Global Institute

o Already Exclusive Commercial representation of Japanese company and European company in India.

o Licensee of several products which are under registration and regulatory approval process in India.

o Proven track record in India and working with over 35 companies including multinationals.

o Managing local India environment. More than 20,000 manufacturers are in India and it can be difficult for any foreign company to navigate in India.

o All our Partner affiliates and employees are fully committed to service excellence and delivery.

Key Advantages of Mala Healthcare

Jayita Basak - Director – University of Wisconsin grad with 15 years experience in Mayo Clinic, Northwestern Memorial,

Quest Diagnostics. Managed P&L in USA.

Milan Sinha – Senior VP, Sales and Marketing – Former General Manager of #1 Pharma company in India (Sun Pharma) and HMR (Hoechst

Marrion Roussel). Heading Specialty Business including Oncology/Auto-Immune.

Business Development – Current Managing Director of Tech Incubator (India), Former Licensing Expert from Tech Park (U.

Massachusetts); IBM Global Business.

Kevin Lei – Operations – Former Dr Reddys and Lupin and local Asia expert.

Pramod Pandey – Regulatory & Government Affairs– Former Top 10 Pharma (India) Head

Bimal Basak – Chair– TATA Management Expert and Chief GM of Largest Central Government Enterprise (India) with

40 yrs experience.

MALA Management Team & Investors

Strategic Advisors

Dr. Mahendra Shah – Executive Advisor, USA

- Venture Partner, Vivo Ventures, San Francisco, US.

- Founder, CEO, Chairman – NextWave Pharma

- Chairman and CEO – First Horizon Pharma. Sold to Shionogi for $1.4 Billion.

- Board member of Unimed, introgen (UMED) Therapeutics (INGN), and others.

Jaisim Shah - Executive Advisor, USA– Board Director, CEO, Founder of Biotechs. Former Chief Business

Officer, PDL Biopharma/Facet Biotech, USA. Former Global VP of Sales and Marketing BMS and Roche. Leader in managing P&L - 20 year reputation in developing brands for blockbuster success for Pfizer, Roche and BMS.

Strategic Advisors

Narendra Rana - Executive Advisor, USA– India Country Head, Devine Group. – Formerly Managing Partner, Amitayus Consulting, USA. Global

experience from start-ups to Fortune 100 companies – 30 years including Managing Director, Knight Ridder Information, International Head Lexis Nexis, and President 2Knowinc.

Strategic Investors

European company & Partner – Licensed product to MALA Healthcare on exclusive basis.

Japanese company & Partner – Licensed product to MALA Healthcare on exclusive basis.

Strategy based on product mix of proprietary and branded generic products

Provide solutions to the unmet medical needs of patients.

Sales and Marketing leadership

All India Distribution and Logistics in over 22 locations

MALA India Operations

Experienced Leadership in India /Asia commercialization and Biotechnology

Ability to rapidly register and commercialize new products

Strong Government Relations & Access

Clear objective to partner and bring biotech and novel pharmaceuticals into India and Asia

MALA’s Competitive Advantage

Superior product– Blue Ocean market development– Fast product uptake – Focused promotion and target positioning– Key Brand Messages

Higher share of voice

Competitive pricing

Access package & Reimbursement support

Key Success Factors

Global shifts - Influencing innovation and commercialization

Emerging Markets especially India and China are the fastest growing areas of development in the world

Blockbusters with mass-market appeal to Targeted niche markets

Exciting Technologies to New Products - Philip Kotler

Kellogg School of Management

Strategic priorities of MALA

Target Partners for Licensing approved treatments for “neglected” diseases for Indian subcontinent

Increase product access for needy patients via advocacy groups and clinician/hospital networks

Increase market penetration in India and Asia for partner

Leverage understanding of local operating environment to foster partnerships with research-based companies

Representative office and Liasioning office in India. – Market Research and Opportunity assessment of Local

market– Fast Track Regulatory approval in Indian subcontinent

including clinical trial and dossier readiness requirements– Top tier commercial infrastructure with domain experts – Ensure high performance of supply chain systems and

product supply, freight and logistics for import/export.– Identify risks in advance and mitigate them with partner. – Regular Board Level communications with partners.

MALA Strategy

MALA-Partner collaboration can create value and reduce collective business risks

Extension of Partner into India. Access complementary strengths

Grow top-line from in-licensed products and expand into new territories including India.

Share risk – regulatory, technology and investment

Grow pipeline and Leapfrog competition- New product categories (oncology, CNS, cardio,

diabetes)

Reduce COGs through INDIA Advantage for bulk/formulations

MALA is seeking partnerships with companies with key attributes

Management - Understands the Asian operating environment

Brand Image – Ethical, top quality, customer-centric

Other– Success in partner’s local market– Transparency in clinical data– Regulatory frameworks for rapid decisions– Exchange of ideas with KOLs– Pre-clinical to Market Launch capabilities

Branded Formulations Branded Formulations

Imaging & Other Imaging & Other Diagnostic ToolsDiagnostic Tools

Clinical Candidates Clinical Candidates

Specialized Specialized TechnologiesTechnologies

Medical ProductsMedical Products

Novel FormulationsNovel Formulations

Biotech Bulk and Biotech Bulk and Finished Products Finished Products

Commercially available Commercially available in Regulated but not in in Regulated but not in

AsiaAsia

Pharma and BiotechPartners

Pharma and BiotechPartners

Potential Areas for PartnershipIncludes Orphan Drugs, Cancer, Inflammation, Plasma, Infectious

Diseases, Novel Technologies with Improved Target product profiles

Thank you

MALA Marketing Process

Brand Strategy - Four Column Model

Disease State Overview Product Profile Patient Segmentation Market Analysis by

Patient Segment:

– Health Care Transaction Model Analysis (including Key Player identification and O/Ts Insights)

– Scenario Analysis– Competitive

Analysis– SWOT

Archetype Assessment

Brand Position, Brand Character and overview of CMEs including Core Value

Message Elements (from PVA Kit)

Strategic Intent

Critical Success Factors

Brand Objectives

Global Target Audience /Key Player Segmentation

– Motivations, Attitudes, Beliefs, Behaviors

– Key Player Objectives

Marketing Programs by Target Audience / Key Player Segment including PRA strategy/programs

Medical Plan and Health Outcomes Plans summary

Market Research Plan Competitive Intelligence

Plan Resources

Implementation Plan

Plan Forecast

Budget

Balanced Scorecard

Measurement/ Evaluation of Brand Plan

Column 1:Analyses & Givens

Column 2:Strategic Ends

Column 3:Strategic Means

Column 4:Operational Plan

Where we are Where we want to beHow we’re going to get there

What we’ll use toget there

How much? By who?By when?

“Textbook” Life Cycle CurveS

ales

/Rx

Development Introduction Growth Maturity Decline

Based on Customer Input

Sal

esHigher, Faster, Longer

Old Paradigm•Peak Share in 5-7 years

1 2 3 4 65 7 8 9 10Years

Product Launch Phase Planning

-2 -1

Launch phase

New Paradigm•Peak Share Much Earlier

Activity Level

Q1 Q2 Q3 Q1 – Q42007 2008

Launch KOL Interaction

P2P

Launch CascadeMeetings throughout RegionPhysician Launch

PostlaunchDoc- discussion groupsT1 super targetsMonthly (6 month duration)Advisory

Board

Sales Rep trainingConditioning pieceTarget Dr and Pharmacy

Detail PieceDosage CardCore Symptom efficacyPatient bookletMonograph

Sales Force TrainingInternal LaunchSales Conference

Sales forceproduct training

Detail PieceDosage CardCore Symptom efficacyNaïve & Switch StratMonographLaunch InvitesFirst Draft / Start Sign Off

Regional Advisory Board

Market Research

Book Venues for Launch.Invites

Advisory Board

Regional Advisory Board

Physician Campaign Allied Pr and Print

Strategy

Website

PharmacyOrderStrategy

Product : Pre - Post Launch Activity Overview

Blunting Strategy

KOL - Speaker Training

Q4

Product - Life Cycle Planning

-2 +4+2L +6 +8 +10

Launch Timeline

Development Timeline A

Development Timeline B

Development Timeline C

Development Timeline D

$$

$ R

eve

nu

e

GOAL based Life -cycle Plan

-Innovation Cycle = 2 years

Innovation = -New indication

-Line Extension

-Major Data

-New Delivery Device

Revenue Cycle = 2/3rds peak sales

by end of 2 nd year

following introduction

of that innovation

Long Term View to Meet Growth Potential of the Molecule

Launch uptake of a brand likely to set future trajectory